JOHNS HOPKINS MEDICINE

ABOUT JOHNS HOPKINS MEDICINE

HEALTH INFORMATION

PATIENT CARE

RESEARCH

EDUCATION

THE INSTITUTIONAL REVIEW BOARDS
VISIT JHM RESEARCH

Photograph of Health Professional

IMAGE OF BLOOD CELL

Photograph of Chemical Container

WHAT'S NEW AT THE IRB

Print This Page

General Information

Guidelines

Organization Policies

Notices & Updates

IRB Forms

Compliance Monitoring Program

HIPAA & Research

Research Training Requirements

Site Map

Contact Us

Alan Mason Chesney Medical Archives

Information for Research Participants

Other Resources

FAQs

Link to eIRB

Search this site:
Full AAHRPP Accreditation

Home > Site Map
Contact Us
Contact Us
Member List JHM-IRB 1
Member List JHM-IRB 2
Member List JHM-IRB 3
 Member List JHM-IRB 5
Member List JHM-IRB X
Staff Contact List
Forms
Miscellaneous JHM-IRB Forms
 Short Form Translation
General Information
IRB Authority
IRB Membership
 JHM IRB Meeting Schedule
Western IRB
Guidelines & Requirements
Access to Study Records
Administration of Gadolinium for Research MRI Procedures
Application of GCP to the Conduct of Clinical Research
Bayview Pharmacy Contact Information
Certificates of Confidentiality
Changes in Research
CIRB Facilitated Review Procedures
Consent - Documenting
Consent Forms Use-Expired
Consent II - How to Prepare a Readable Consent Form
Consent-Waiver / Alteration
Continuing Review Guidance
Convened IRB Review
Coordinating Center Functions and Multi-Site Studies
Department & Ancillary Reviews
Departmental Communication to Patients about Ongoing Research
Devices Medical-Investigational
Drug Research
Exempt Research
Expedited Review Process
Expressing Concerns or Complaints about Research
Fees for JHM IRB and WIRB Review of Research Protocols
GCRC Data Safety Monitoring
Gene Transfer Research
Guidance for faculty conducting research involving the Baltimore City Health Department
Guidance on Complying With Federal Requirements to Obtain Permission from Both Parents for Certain Studies Involving Children, Pregnant Women, Fetuses, or Neonates
Guidances Relating to Compliance, Laws & Regulations
Guidances Relating to Consent
Guidances Relating to Investigator Responsibilities
Guidances Relating to Reporting Requirements
Guidances Relating to Research Activities - IRB Review Processes
Guidances Relating to Specific Types of Research
Guidelines & Requirements
HIPAA IRB DHHS Guidance
How and When a Principal Investigator Should Report Death of a JHM Research Participant
Humanitarian Use Devices (HUD)
Inclusion of Howard County General Hospital as a study site
IND Investigator Inquiry
Informed Consent for Minors in Research Studies
Informed Consent I - What does informed consent mean in the human research context ?
Informed Consent III - FDA regulated studies
International Research
Investigator Responsibilities
 Investigators as Study Participants (Self-Experimentation)
Investigators Brochure
JHH Nursing Research Approval Process
JHM IRB Guidelines for Clinical Genetics Research
JHU Nursing: Research Requirements
Johns Hopkins HealthCare Data Sharing Committee Guidance
Maryland Law
Maryland Reporting Obligations that May Apply
Medstar Reciprocity Agreement
Monitoring Visits
MRI Language
Non-Compliance by Investigator
Obtaining and Documenting Informed Consent Of Subjects Who Do Not Speak English
Obtaining the Permission of Both Parents for Certain Research: Steps to Follow
Oncology Therapeutic Research
Online Resources
Pathology Guidance
Patient Recruitment and Referral for Research
Pharmacy and IDS Services: JHH
Pharmacy Services:Bayview
Post-Doc Fellow Participation
Procedures for Enrollment of Children in Baltimore City DSS Custody as Research Subjects
Project Closed to Accrual, in Data Analysis Only, or Terminated
QI/QA Guidance
Recruiting Study Subjects and Reasonable Payment (Remuneration)
Recruitment Students/Employees
Registration of Clinical Trials
Regulatory Definitions
Reporting Protocol Deviations
Reporting-Institution/Gov't
Research Databases
Research Using FDA Test Articles
Review Processes for Projects Conducted at Institutions with which Hopkins has Reciprocity Agreements
School of Nursing Departmental Signatures Policy
Sedation Guidelines
Significant Differences in FDA and DHHS Regulations
Single Case Report Policy
Submission of Sponsor IND Safety Reports
Training Requirements for Human Subjects Research
Use of Human Biological Materials In Research
Web Access to IRB Application Status
WIRB Review of JHM Studies
HIPAA
HIPAA FAQs
HIPAA Forms
HIPAA Guidances
HIPAA Policies
 Definition of De-Identified Data
Definition of Limited Data Set
HIPAA Information
Monitoring
Common Compliance Terms
Compliance Monitoring Program
Compliance Monitoring Program Educational Seminars
How To Prepare for an FDA Inspection
 Internal “For Cause” or “Directed” Audit Process and Site Preparation
Internal Monitoring Process and Site Preparation
Policies and Guidances Relating to Monitoring
Purpose of OSHR Monitoring and Auditing
Notices / Updates
From the Desk of the Vice Dean
2001 Updates
2002 Updates
eIRB Training Classes
eIRB Upgrade
 IRB Compliance monitoring - Educational Sessions
New HIPAA training course
Notices and Updates
Third Compliance Monitoring Session at JHU and Bayview
Organization Policies
Organization on Meeting Procedures Policy No. 103.5
Organization ORA.1: Policy On Sponsor Responsibilities
Organization Policies
Organization Policy for Participation of Post-Doctoral Fellows In Human Subjects Research Policy No. 111.3
Organization Policy for Training and Evaluation of IRB Members and Chairs Policy No. 107.3
Organization Policy Investigational Drug Service (IDS) and OHSR Policy No. 103.20
Organization Policy List of IRB Members Policy No. 103.4
Organization Policy on Allegations of Undue Influence over the JHM IRB Policy No. 109.4
Organization Policy on Ancillary Reviews for Human Subject Research Studies Policy No. 103.10(a)
Organization Policy on Assignment of IRB Review Policy No. 103.10(b)
Organization Policy on Bone Marrow Transplant Procedures in Children Policy No. 102.6
Organization Policy on Clinical Investigations with FDA “Test Articles” Policy No. FDA 50.2
Organization Policy on Clinical Radiation Research Committee (CRRC), the Radioactive Drug Research Committee (RDRC) and the JHM IRB Policy No. 103.21
Organization Policy on Committee on Conflict of Interest (CCOI) and the JHM IRB Policy No. 103.11
Organization Policy on Communicating JHM IRB Actions to Investigators Policy No. 109.2
Organization Policy on Complaints from Research Participants, Investigators and Research Staff, the Community, etc. Policy No. 109.3
Organization Policy on Consultants Policy No. 107.2
Organization Policy on Continuing Review of Approved Research Policy No. 109.6(b)
Organization Policy on Convened Meeting Primary Reviewer System Policy No. 111.1
Organization Policy on Cooperative Research and Multi-Center Studies Policy No. 114.2
Organization Policy on Credentials of Research Team and Documentation Required from Non-Hopkins IRBs and Study Sites Policy No. 103.23
Organization Policy on Data and Safety Monitoring of Proposed Research Policy No. 103.6 (c)
Organization Policy on Determination of “Human Subject Research” and Exempt Research Policy No. 102.1
Organization Policy on Development and Communication Policy No. 103.18
Organization Policy on Device Research Requirements Policy No. 103.24(b)
Organization Policy on Drug Use and Control in Clinical Investigations Policy No. 103.19(a)
Organization Policy on Exempt Research Policy 101.1
Organization Policy on Expedited Review of Proposed Research Policy No. 110.1
Organization Policy on Expired JHM IRB Approval: Protocols and Consent Forms Policy No. 109.7
Organization Policy on Financial and Personal Conflict of Interest Policy for IRB Members Policy No. 111.11
Organization Policy on HSPP Assurance of Compliance with DHHS Policy Policy 103.1
Organization Policy on Human Subjects Research Compliance Training Policy No. 103.12
Organization Policy on Humanitarian Use Devices Policy No. FDA 814.1
Organization Policy on Informed Consent Process and Documentation Policy No. 116.1
Organization Policy on Institutional Biosafety Committee (IBC) and the JHM IRB Policy No. 103.22
Organization Policy on Institutional Review of IRB Approved Research Policy No.112.1
Organization Policy on Investigator Non-Compliance Policy No. 103.7
Organization Policy on Investigators as Study Participants Policy No. 111.9
Organization Policy on IRB Actions Policy No. 109.5
Organization Policy on IRB Actions to Disapprove Research Policy No. 46.109.6(a)
Organization Policy on IRB Authority to Review Research Policy No. 109.1(b)
Organization Policy on IRB Composition and OHSR Staff Qualifications Policy No. 107.1
Organization Policy on IRB Records Policy No. 115.1
Organization Policy on IRB Review of Federal-Approved Consent Documents for Federally-Supported Multicenter Clinical Trials Policy No. 116.4
 Organization Policy on JHM Facilitated Review for NCI Central IRB and NCI Pediatric Central IRB Policy No. 114.1
Organization Policy on Maryland State Law Requirements: Maryland House Bill No. 917 (Hubbard Act) Policy No. SL1
Organization Policy on Minimizing Risks Associated with Research Participation Policy No. 111.10
Organization Policy on Monitoring the Consent Process and Research Procedures in Ongoing Research Policy No. 109.8
Organization Policy on Payment or Remuneration to Human Subjects Policy No. 111.2
Organization Policy on Pharmacy and Therapeutics Committee and JHM IRB Policy No. 103.19
Organization Policy on Primary Reviewer as Consent Designee for the Study Being Reviewed Policy No. 103.13
Organization Policy on Principal Investigator Responsibilities Policy No. 103.24a
Organization Policy on Privacy and Confidentiality Policy No. 111.12
Organization Policy on Protocol Record Retention Requirements for Investigators Policy No. 115.2
Organization Policy on Provision of Research Samples for Clinical Testing Policy 102.7
Organization Policy on Quorum, Voting Status of IRB Alternate Members, and IRB Member Attendance Policy No. 108.1
Organization Policy on Recruitment of Students Policy No. 111.4(b)
Organization Policy on Recruitment of Study Subjects Policy No. 111.13
Organization Policy on Reporting Policy No. 103.6(a)
Organization Policy on Reports of Unanticipated Problems Involving Risks to Participants or Others Policy No. 103.6(b)
Organization Policy on Research Involving Children Policy No. D403
Organization Policy on Research Involving Human Embryonic Stem Cells, Germ Cells,and Stem Cell-Derived Test Articles Policy No. 102.4
Organization Policy on Research Involving Pregnant Women, Fetuses, Neonates Policy No. B203
Organization Policy on Research Involving Vulnerable Populations Policy No. 111.8
Organization Policy on Responsibility for the Human Subjects Protection Program (HSPP) Policy No. 109.1(a)
Organization Policy on Review of Changes in Approved Research Policy No. 103.9
Organization Policy on Review of In Vitro Diagnostic Device Protocols Policy No. FDA 50.1
Organization Policy on Review of Research Involving Prisoners Policy No. C304
Organization Policy on Sample Size Policy No. 111.7
Organization Policy on Scientific Review Policy No. 111.5
Organization Policy on Sedation Policies for Research Protocols Involving Diagnostic, Operative and Invasive Procedures Policy No. 111.6
Organization Policy on Signing the Consent/Assent Document Policy No. 117.1
Organization Policy on Single Case Reports and Case Series Policy No. 102.3
Organization Policy on State of Maryland Mandatory Disease and Condition Reporting -Diseases and Conditions Reportable by Health Care Providers and Others Policy No. SL2
Organization Policy on Support for the JHM IRB Policy No. 103.16
Organization Policy on Suspension or Termination of IRB Approved Research Policy No. 113.1
Organization Policy on the Definition of Research As It Applies to Clinical Practice, Quality Improvement/Quality Assurance, and Public Health Activities Policy No. 102.2
Organization Policy on Transfer of Protocol among JHM IRBs Policy No. 103.14
Organization Policy on Translation of Consent Documentation Policy No. 116.3
Organization Policy on Visitors to the IRB Policy No. 103.15
Organization Statement of Commitment to the Principles Governing Human Subjects Research Policy No. 103.3
Policy No. 101.2 Organization Policy on Research Laboratory Testing Results
Policy No. 102.2(a) Organization Policy on Quality Improvement/Quality Assurance Activity
Policy No. 103.25 Organization Policy on Registration of Clinical Trials
Policy No. 103.26 Organization Policy on Electronic Submission of Information to the JHM IRBs
Policy No. 103.6(b)(i) Organization Policy on Reporting Death of a JHM Research Participant
Policy No. 111.4 (a) Organization Policy on Recruitment of Employees
Policy No. 116.5 Organization Policy on Use of Research Data in Cases of Questionable Consent Documentation
Research Participants
Information for Research Participants
Useful Links
Resources

 

 

If you have any comments, questions or suggestions
you may contact the JHM IRB at:

p: 410.955.3008 | f: 410.955.4367 or 443.287.5353 | e: jhmirb@jhmi.edu

 


Site Maps | FAQs | Maps & Directions | Privacy Policy | Intranet | Contact JHM | Media Inquires | Fund For JHM
JOHSN HOPKINS HOSPITAL & HEALTH SYSTEM
JOHNS HOPKINS UNIVERSITY
JOHNS HOPKINS MEDICINE